We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

191 hedge funds and large institutions have $4.36B invested in Intercept Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 95 increasing their positions, 47 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

102% more repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 47

5% less funds holding

Funds holding: 200191 (-9)

13% less capital invested

Capital invested by funds: $5.01B → $4.36B (-$646M)

15% less call options, than puts

Call options by funds: $115M | Put options by funds: $136M

21% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 34

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
191
Holders Change
-9
Holders Change %
-4.5%
% of All Funds
5.15%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
27
Increased
95
Reduced
47
Closed
34
Calls
$115M
Puts
$136M
Net Calls
-$20.2M
Net Calls Change
-$51.9M
Name Holding Trade Value Shares
Change
Change in
Stake
CCM
201
Catapult Capital Management
New York
-$2.26M -8,000 Closed
QIM
202
Quantitative Investment Management
Virginia
-$1.55M -5,500 Closed
MIM
203
Monashee Investment Management
Massachusetts
-$1.41M -5,000 Closed
NG
204
NatWest Group
United Kingdom
-$1.28M -4,540 Closed
PP
205
Paloma Partners
Connecticut
-$1.2M -4,249 Closed
Tudor Investment Corp
206
Tudor Investment Corp
Connecticut
-$945K -3,350 Closed
3NC
207
300 North Capital
California
-$736K -2,609 Closed
GGHC
208
Gilder Gagnon Howe & Co
New York
-$657K -2,328 Closed
LCS
209
Levin Capital Strategies
New York
-$564K -2,000 Closed
NCCM
210
Nine Chapters Capital Management
New Jersey
-$536K -1,900 Closed
CSS
211
Cubist Systematic Strategies
Connecticut
-$421K -1,493 Closed
Verition Fund Management
212
Verition Fund Management
Connecticut
-$407K -1,442 Closed
DFIM
213
Detwiler Fenton Investment Management
Massachusetts
-$396K -1,405 Closed
Envestnet Asset Management
214
Envestnet Asset Management
Illinois
-$393K -1,393 Closed
BPC
215
Banque Pictet & Cie
Switzerland
-$282K -1,000 Closed
BCM
216
BlueCrest Capital Management
Jersey
-$282K -1,000 Closed
IG
217
ING Group
Netherlands
-$282K -1,000 Closed
ID
218
Integral Derivatives
New York
-$202K -758 Closed
MPWT
219
MassMutual Private Wealth & Trust
Connecticut
-$161K -572 Closed
Creative Planning
220
Creative Planning
Kansas
-$51K -180 Closed
SFPIA
221
Stevens First Principles Investment Advisors
California
-$42K -150 Closed
PHK
222
Point72 Hong Kong
Hong Kong
-$30K -107 Closed
MUS
223
Mitsubishi UFJ Securities
Japan
-$17K -60 Closed
CLOS
224
Compagnie Lombard Odier SCmA
Switzerland
-$11K -40 Closed
MFS
225
MSI Financial Services
Massachusetts
+$266 +1 New

ICPT Hedge Fund Activity: Q2 2015 in Review

191 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q2 2015, worth a combined $4.36B — down 13% from $5.01B a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of ICPT and 27 opened new positions — a net loss of 7 holders — while 47 trimmed existing stakes and 95 added.

The largest buyer was Ameriprise, adding an estimated $179M. The largest seller was Millennium Management, cutting an estimated $87.5M.

  • 191 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q2 2015, down from 200 in Q1 2015.
  • Funds reported $4.36B of Intercept Pharmaceuticals, Inc. stock for Q2 2015, down 13% quarter-over-quarter.
  • 27 funds opened new Intercept Pharmaceuticals, Inc. positions in Q2 2015 and 34 closed out, a net change of -7 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q2 2015 was Ameriprise, an estimated $179M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q2 2015 was Millennium Management, an estimated $87.5M sold.

Based on aggregated 13F filings for Q2 2015.